Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
REGULATORY
Japan Approves Mefeego as First Abortion Pill
The Japanese health ministry gave an official stamp of approval for Linepharma’s Mefeego (mifepristone/misoprostol) on April 28, making it the first oral abortion pill in the country. The drug is indicated for medical abortion for women with confirmed intrauterine pregnancy…
To read the full story
Related Article
- Japan Partially Eases Rule for Use of Abortion Pill Mefeego
December 2, 2024
- MHLW Panel Puts a Hold on Proposed Use of Abortion Pill at Clinics Without Beds
September 26, 2024
- Panel Conditionally OKs Change to Allow Use of Abortion Pill at Clinics Without Beds
August 28, 2024
- LDP Members Fret over Easier Access to Abortion Pill Mefeego
July 29, 2024
- 68.3% of Public Comments Supported Mefeego Approval: MHLW
May 16, 2023
- OB/GYN Society Aims for Early Use of Oral Abortion Pill at Clinics without Beds
May 12, 2023
- Health Ministry Panel OKs Japan’s First Abortion Pill with Official Go-Ahead Set for May
April 24, 2023
- Abortion Pill Mefeego’s Japan Panel Review Rescheduled for April 21
April 18, 2023
- Lawmakers Split 50/50 on Abortion Pill, No Conclusion at LDP Panel
April 13, 2023
- Public Comments 2 to 1 in Favor of Approving Abortion Pill: MHLW
March 27, 2023
- Review of Abortion Pill Postponed amid Flock of Public Comments
March 24, 2023
- Oral Abortion Pill Mefeego Up for Another Round of Panel Reviews on March 24
March 20, 2023
- OB/GYN Group Urges MHLW to Facilitate Access to Oral Abortion Drug
February 24, 2023
- Panel OKs Japan’s First Abortion Pill, but Upper Organ to Review It Again after Public Comments
January 30, 2023
REGULATORY
- LDP Tariff Task Force Broadly OKs First Proposal
April 22, 2025
- GSK’s Blenrep, Moderna RSV Jab Edge Closer to Japan Approval with Panel OK
April 22, 2025
- Ruling Coalition Wary of Scrapping Coverage for OTC-Like Drugs
April 21, 2025
- Diuretic, Hypertension Drugs, Zolgensma under PMDA Risk Review
April 21, 2025
- Chugai’s DMD Gene Therapy Now in Line for Conditional Approval
April 21, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…